434,549 Shares in Elevance Health, Inc. $ELV Bought by Danica Pension Livsforsikringsaktieselskab

Danica Pension Livsforsikringsaktieselskab purchased a new stake in shares of Elevance Health, Inc. (NYSE:ELV) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 434,549 shares of the company’s stock, valued at approximately $140,411,000. Elevance Health accounts for 2.2% of Danica Pension Livsforsikringsaktieselskab’s holdings, making the stock its 15th biggest position. Danica Pension Livsforsikringsaktieselskab owned approximately 0.20% of Elevance Health at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its position in shares of Elevance Health by 0.6% during the 3rd quarter. Vanguard Group Inc. now owns 22,998,645 shares of the company’s stock valued at $7,431,322,000 after acquiring an additional 141,747 shares during the period. Wellington Management Group LLP raised its holdings in Elevance Health by 4.8% in the 3rd quarter. Wellington Management Group LLP now owns 6,621,297 shares of the company’s stock worth $2,139,473,000 after purchasing an additional 303,099 shares during the period. Artisan Partners Limited Partnership boosted its position in Elevance Health by 24.5% during the third quarter. Artisan Partners Limited Partnership now owns 4,576,805 shares of the company’s stock worth $1,478,857,000 after purchasing an additional 901,626 shares in the last quarter. First Eagle Investment Management LLC grew its holdings in Elevance Health by 25.0% in the third quarter. First Eagle Investment Management LLC now owns 3,998,603 shares of the company’s stock valued at $1,292,029,000 after purchasing an additional 798,457 shares during the period. Finally, Norges Bank acquired a new stake in Elevance Health in the second quarter valued at approximately $1,148,379,000. Hedge funds and other institutional investors own 89.24% of the company’s stock.

Elevance Health Stock Up 1.4%

ELV stock opened at $296.14 on Wednesday. The company has a current ratio of 1.54, a quick ratio of 1.54 and a debt-to-equity ratio of 0.70. The firm has a 50-day moving average of $335.31 and a two-hundred day moving average of $334.16. Elevance Health, Inc. has a 12 month low of $273.71 and a 12 month high of $458.75. The company has a market cap of $65.36 billion, a price-to-earnings ratio of 11.79, a PEG ratio of 1.60 and a beta of 0.51.

Elevance Health (NYSE:ELV) last issued its earnings results on Wednesday, January 28th. The company reported $3.33 earnings per share for the quarter, topping the consensus estimate of $3.10 by $0.23. Elevance Health had a return on equity of 15.59% and a net margin of 2.84%.The business had revenue of $49.31 billion for the quarter, compared to analysts’ expectations of $49.52 billion. During the same period in the previous year, the firm posted $3.84 EPS. The business’s revenue for the quarter was up 9.6% compared to the same quarter last year. Elevance Health has set its FY 2026 guidance at 25.500- EPS. As a group, analysts forecast that Elevance Health, Inc. will post 33.96 earnings per share for the current fiscal year.

Elevance Health Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, March 25th. Stockholders of record on Tuesday, March 10th will be given a dividend of $1.72 per share. This represents a $6.88 annualized dividend and a dividend yield of 2.3%. The ex-dividend date of this dividend is Tuesday, March 10th. This is a positive change from Elevance Health’s previous quarterly dividend of $1.71. Elevance Health’s dividend payout ratio is presently 27.39%.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on ELV shares. Royal Bank Of Canada downgraded Elevance Health from an “outperform” rating to a “sector perform” rating and set a $358.00 target price for the company. in a research note on Tuesday, February 3rd. Wall Street Zen cut shares of Elevance Health from a “buy” rating to a “hold” rating in a research note on Sunday, February 8th. Deutsche Bank Aktiengesellschaft restated a “hold” rating and set a $332.00 price objective on shares of Elevance Health in a research report on Thursday, January 29th. JPMorgan Chase & Co. increased their price objective on shares of Elevance Health from $394.00 to $397.00 and gave the company an “overweight” rating in a report on Monday, February 2nd. Finally, Mizuho dropped their target price on shares of Elevance Health from $413.00 to $350.00 and set an “outperform” rating on the stock in a research report on Wednesday, March 11th. Twelve investment analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $387.40.

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.